Project Grant R03CA308537
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput technological tools for tracking the fate of prematurely terminated transcripts in cancer cells. The project, which extends through February 28, 2029, focuses on advancing understanding of alternative polyadenylation (APA) events—RNA processing mechanisms that drive oncogenesis independent of DNA...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Harvard Medical School a Project Grant of $151,040 under the Cancer Research Manpower program (CFDA 93.398) on January 8, 2026, with a completion date of December 31, 2028. This award supports a research project investigating the direct impact of N6-methyladenosine (M6A) deposition on messenger RNA regulation, with specific focus on the METTL3 enzyme's role in acute myeloid leukemia (AML) cell survival. The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary Yale University received a $150,104 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded January 16, 2026, with a completion date of August 31, 2028. This award supports research investigating the impact of aberrant 5-methylcytosine (M5C) messenger RNA (mRNA) modifications on translation initiation and cancer development. The research focuses on determining how dose-sensitive M5C modifications in...
- Federal Grant Award Summary The National Cancer Institute awarded a $211,112 Project Grant to Harvard Medical School (President and Fellows of Harvard College) on August 14, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award supports basic cancer research investigating the role of Replication Protein A (RPA) in polymerase theta-mediated end-joining (TMEJ), a mutagenic DNA double-strand break (DSB) repair pathway that cancer cells dependent on deficient homologous...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Harvard College's Office for Sponsored Programs a Project Grant of $604,102 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop innovative three-dimensional (3D) bioprinted vascular cancer models. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, will deliver in vitro human and murine cancer models utilizing microporous embedded printing technology to enable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a Project Grant of $148,626 under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025, through April 30, 2028. This award supports research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The funding enables the institution to provide biomedical training opportunities and research career...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary New York University School of Medicine received a $149,190 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025, with completion by May 6, 2027. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The funded research project focuses on elucidating the mechanisms of DNA...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Massachusetts Medical School $136,840 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, for a project extending through May 11, 2028. This project grant funds research investigating replication gap suppression mechanisms in chemoresistant BRCA1 and BRCA2 (BRCA) mutant hereditary breast and ovarian cancers (HBOC). The research aims to identify critical factors contributing...
The National Cancer Institute awarded a $167,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Massachusetts Medical School, effective May 1, 2026 through April 30, 2028. This award supports the development and application of HARP-SEQ (a novel, highly sensitive sequencing method) to map 3-methylcytidine (M3C) RNA modifications in messenger RNA at single-nucleotide resolution. The project integrates advanced chemical labeling and enrichment strategies with high-throughput sequencing and bioinformatics analysis to comprehensively characterize M3C distribution patterns in mRNA across various cancer cell lines, primary tumor samples, and matched normal tissues. The research addresses a significant gap in epitranscriptomic understanding by resolving current controversies regarding M3C's presence and function in mRNA, which has been poorly understood due to conflicting experimental evidence and inadequate detection methods. By establishing this methodological capability and applying it to cancer research contexts, the project is expected to advance understanding of cancer-associated epitranscriptomic changes and provide insights into how RNA modifications contribute to oncogenesis, ultimately supporting the Cancer Biology Research program's objective of providing fundamental information on the cause and nature of cancer to enable improved prevention, detection, and treatment strategies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $167.5k | 4/30/26 |